Acalabrutinib in Patients (pts) with Waldenstrom Macroglobulinemia (WM)

Roger G. Owen,Helen McCarthy,Simon Rule,Shirley DSa,Sheeba K. Thomas,Francesco Forconi,Thomas C. Anderson,Marie José Kersten,Pier Luigi Zinzani,Sunil Iyengar,Jaimal Kothari,Monique C. Minnema,Efstathios Kastritis,Raquel Izumi,J. Greg Slatter,Diana Mittag,Helen Wei,Dih-Yin Chen,Priti Patel,Richard R. Furman

Acalabrutinib in Patients (pts) with Waldenstrom Macroglobulinemia (WM)

2018

7501Background: Bruton tyrosine kinase (BTK) is a clinically validated target in WM. Acalabrutinib is a highly selective, potent, covalent BTK inhibitor that we evaluated in a Phase 2 study of pts ...

Keywords:

Bruton's tyrosine kinase
Pathology
Refractory
Oncology
Waldenstrom macroglobulinemia
Acalabrutinib
Internal medicine
Medicine
therapy naive
in patient
Immunology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations